Investigating the role of a PRMT5 in Ewing sarcoma and its potential as a target for treatment
Professor Clare Davies and Dr Susanne Gatz explore whether PRMT5 inhibitors could be an effective and kinder treatment for Ewing sarcoma.
Exploring surrounding epigenetic influences in Ewing sarcoma
Dr Sara Sánchez Molina is investigating how a certain gene drives Ewing sarcoma in order to find a better way to treat it.
Evaluating a new antibody-based targeted treatment for medulloblastoma
Dr Laura Donovan is testing a targeted treatment for medulloblastoma in the hopes of giving incurable patients new treatment options.
Using tiny particles in blood and cerebrospinal fluid to improve the diagnosis and treatment of childhood brain tumours
Dr Timothy Ritzmann aims to improve ependymoma care and treatment by harnessing the potential of extracellular vesicles.
Understanding new treatment options for when treatment for neuroblastoma doesn’t work or the cancer grows back
Dr Jess Morgan at the University of York will review the latest experimental treatments for hard-to-treat neuroblastoma to help with decision-making.
Understanding existing research about ambulatory chemotherapy for children and young people
Dr Jess Morgan at the University of York hopes to understand what we already know about using portable chemotherapy pumps for children with cancer.
Tracking individual osteosarcoma cells to understand how they dodge chemotherapy
Dr Lucia Cottone at University College London hopes to understand how osteosarcoma cells become resistant to chemotherapy, which has a big impact on patient survival.
Exploring how osteosarcoma cells spread and survive elsewhere in the body
Dr Olivier Pardo at Imperial College London aims to find out how osteosarcoma cells survive the bloodstream and spread elsewhere in the body.
Optimising drug treatment for childhood cancer patients
It is particularly difficult to treat some groups of childhood cancer patients, especially infants in their first weeks of life. This application is to fund this rapidly developing research programme for two years, involving the treatment of 150-200.